New £1.6 million research project to support development of drug candidate for the treatment of motor neuron disease (MND)
Our researchers have been awarded funding to support their partnership with Aclipse Therapeutics and advance the translational development of M102 - a drug candidate for the treatment of motor neuron disease (MND).
Imaging technique proves effective in measuring mitochondrial dysfunction in motor neuron disease (MND)
A non-invasive imaging technique called 31-phosphorus magnetic resonance spectroscopy was used to assess mitochondrial function in patients with MND and could be used to measure the effectiveness of future treatments.
Treating neurodegenerative diseases by boosting mitochondria
A new partnership between the Sheffield Institute for Translational Neuroscience (SITraN) and Nanna Therapeutics will advance mitochondrial drug discovery research for neurodegenerative diseases.